Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.

Blood Cancer J · 2022 · PMC9021259 · PMID 35443742

Europe PMC DOI

hedged sentences

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

showed a trendP = 0.066so close (0.05 < p ≤ 0.1)

Viale-A time to deterioration in HRQoL Compared with placebo + azacitidine patients, venetoclax + azacitidine patients showed a trend towards longer time to deterioration in GHS/QoL (median in months: 16.5 vs. 9.3, P = 0.066) and fatigue (9.3 vs. 8.6, P = 0.189) (Fig. 1 ; Table 1 ).

also in 53,322 other papers

a slight trendno p-value reported

In contrast, the time to deterioration was similar between treatment groups in older patients (≥75 years) with a slight trend towards prolongation of HRQoL with venetoclax combination therapy; this finding is important as elderly patients tend to have worse clinical outcomes and HRQoL [ 7 , 43 ].

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.